Brought to you by 
Chugai gets rights to Two Cells' gMSC1 for knee chondrogenesis
29 Sep 2021
Executive Summary
Chugai Pharmaceutical Co. Ltd. received exclusive Japanese development and distribution rights to Two Cells Co. Ltd.'s preclinical cell therapeutic gMSC1 for knee chondrogenesis. Chugai may also negotiate for a license in ex-Japanese territories.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chugai gets rights to Two Cells' gMSC1 for knee chondrogenesis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice